No connection

Search Results

INGN vs KPTI

INGN
Inogen, Inc.
BEARISH
Price
$6.33
Market Cap
$172.4M
Sector
Healthcare
AI Confidence
85%
KPTI
Karyopharm Therapeutics Inc.
BEARISH
Price
$8.00
Market Cap
$180.3M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
INGN
--
KPTI
--
Forward P/E
INGN
-20.42
KPTI
-1.83
P/B Ratio
INGN
0.9
KPTI
-0.5
P/S Ratio
INGN
0.49
KPTI
1.23
EV/EBITDA
INGN
-7.36
KPTI
-4.3

Profitability

Gross Margin
INGN
44.24%
KPTI
9.93%
Operating Margin
INGN
-12.21%
KPTI
-52.36%
Profit Margin
INGN
-6.52%
KPTI
-134.21%
ROE
INGN
-12.43%
KPTI
--
ROA
INGN
-6.35%
KPTI
-41.56%

Growth

Revenue Growth
INGN
2.0%
KPTI
11.6%
Earnings Growth
INGN
--
KPTI
--

Financial Health

Debt/Equity
INGN
0.09
KPTI
--
Current Ratio
INGN
3.12
KPTI
1.12
Quick Ratio
INGN
2.52
KPTI
0.98

Dividends

Dividend Yield
INGN
--
KPTI
--
Payout Ratio
INGN
0.0%
KPTI
0.0%

AI Verdict

INGN BEARISH

INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.

Strengths
Very low leverage (Debt/Equity 0.09)
Strong short-term liquidity (Current Ratio 3.12)
Healthy Gross Margin (44.24%)
Risks
Critical operational failure (Piotroski F-Score 1/9)
Stagnant top-line growth (YoY Revenue Growth 2.00%)
Persistent net losses and negative ROE (-12.43%)
KPTI BEARISH

KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.

Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness

Compare Another Pair

INGN vs KPTI: Head-to-Head Comparison

This page compares Inogen, Inc. (INGN) and Karyopharm Therapeutics Inc. (KPTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile